Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06306521
Other study ID # 20235517
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 29, 2024
Est. completion date February 2029

Study information

Verified date March 2024
Source Rady Pediatric Genomics & Systems Medicine Institute
Contact Lauren Olsen, MSN
Phone 858-576-1700
Email lolsen1@rchsd.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to test a new method for newborn screening using whole genome sequencing, called BeginNGS. Parents will be approached to provide informed consent to enroll their newborns in prenatal, postnatal, and outpatient settings. The main questions this study aims to answer are: What is the utility of BeginNGS as compared to state newborn screening? What is the acceptability and feasibility of BeginNGS as compared to state newborn screening? What is the cost effectiveness of BeginNGS as compared to state newborn screening? Enrolled newborns will have a blood sample taken and will receive the BeginNGS test. Newborns will have also had the state newborn screening test.


Description:

Each year 98% of US newborns receive screening (NBS) of dried blood spots (DBS) for at least 35 Recommended Uniform Screening Panel (RUSP) genetic disorders for diagnosis and treatment at/before onset of symptoms. About 6,600 true positive infants are identified per year. NBS is well-accepted and has proven clinical utility. Between 2010 and 2022, however, while many new therapeutic interventions for childhood genetic diseases showed clinical utility and/or were approved by the Food and Drug Administration (FDA), only 6 disorders were added to the RUSP. As a result, ~700 childhood genetic diseases have effective treatments but are not yet screened by NBS, and affected children experience delayed diagnosis and treatment, and poor outcomes. To solve this problem the investigators are developing BeginNGS - NBS by genome sequencing (GS) of DBS for, ultimately, ~700 severe, childhood genetic diseases with effective therapeutic interventions. BeginNGS is adaptive: genetic disorders are added (or removed) as evidence emerges that early treatment improves (or does not improve) outcomes. BeginNGS version 1 (v1, 388 genetic disorders) had good sensitivity (88.8%) and false positive rate (0.27%) in a retrospective study of 458,000 subjects. An exploratory prospective clinical trial comparing BeginNGS v2 (with 409 disorders) and rapid diagnostic genome sequencing (RDGS) identified reportable findings in 24 (34%) of 71 acutely ill newborns who were not suspected of having a genetic disease. Only 2 of those disorders were detected by standard NBS. The investigators propose a single group, multicenter, adaptive clinical trial to compare utility, acceptability, feasibility, and cost effectiveness of BeginNGS (experimental intervention) with standard NBS (control) in a minimum of 10,000 neonates (aged <28 days, maximum of 100,000). The primary objective of the trial is to generate evidence to support broad implementation of BeginNGS. An adaptive design was chosen rather than a traditional, fixed design to allow accumulating results to make the trial more efficient, informative, and ethical by addition or removal of BeginNGS disorders and genetic variants, population enrichment (for minority racial, ethnic, and ancestral groups), and sample size re-estimation. Adaptive design will also facilitate meta-analysis with other clinical trials of NBS-by-GS, providing greater power to test utility in ultra-rare genetic diseases. NBS-by-GS has the potential to transform the way childhood genetic diseases are diagnosed and treatments started. Preliminary data suggest that national adoption of BeginNGS in all births has the potential to improve outcomes of >50,000 US children per year.


Recruitment information / eligibility

Status Recruiting
Enrollment 10000
Est. completion date February 2029
Est. primary completion date February 2029
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 1 Day to 28 Days
Eligibility Inclusion Criteria: 1. Neonates (<28 days old) at enrollment sites. 2. Parents must have identified a primary care provider (or group). Exclusion Criteria: 1. Neonates whose mother is less than 18 years of age. 2. Neonates who are wards of the state. 3. Neonates whose parent/legal guardian is unable to provide consent. 4. Parents with a home address outside the US or jurisdiction of the enrollment sites. 5. Neonates or fetuses who are ill and in whom enrollment or sampling is anticipated to interfere with healthcare provision at delivery. For example, fetuses or neonates who are likely to require transfer to a higher level of care, such as to a Level IV NICU upon delivery. 6. Neonates who are under consideration for a rapid diagnostic genome sequence or other diagnostic genetic testing. 7. Neonates who are not expected to survive the neonatal period.

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
BeginNGS Test
Genomic sequencing that screens for over 400 genetic diseases.

Locations

Country Name City State
United States Rady Children's Hospital San Diego San Diego California

Sponsors (1)

Lead Sponsor Collaborator
Rady Pediatric Genomics & Systems Medicine Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of the clinical utility of BeginNGS and standard of care (state NBS), defined by the proportion of enrollees likely to benefit (likely to have an improved outcome) from an indicated therapeutic intervention The proportion of enrollees likely to benefit (likely to have an improved outcome) from an indicated therapeutic intervention (as per an electronic clinical management system, Genome-to-Treatment, GTRx) 5 years
Secondary Utility secondary outcome 1 The proportion of BeginNGS and state NBS of DBS that are positive (Positive rate) 5 years
Secondary Utility secondary outcome 2 The proportion of BeginNGS and state NBS of DBS positive results that are confirmed (true positive rate and positive predictive value) 5 years
Secondary Utility secondary outcome 3 The proportion of BeginNGS and state NBS of DBS that are true positive and diagnosed during infancy. 5 years
Secondary Utility secondary outcome 4 The proportion of BeginNGS and state NBS of DBS that are true positive and diagnosed at study end. 5 years
Secondary Utility secondary outcome 5 The proportion of BeginNGS and state NBS of DBS that are positive and in whom an indicated therapeutic intervention was commenced by study end. 5 years
Secondary Utility secondary outcome 6 The proportion of BeginNGS and state NBS of DBS that are positive and in whom a disease outcome changed due to a therapeutic intervention by study end. 5 years
Secondary Utility secondary outcome 7 Subgroup analysis of clinical utility (as defined by the primary outcome measure) by race (black, white, Asian), ethnicity (Hispanic, non-Hispanic), genetic ancestry, and disorder group 5 years
Secondary Utility secondary outcome 8 Subgroup analysis of positive rate (secondary utility outcome measure 1) by race, ethnicity, genetic ancestry, and disorder group. 5 years
Secondary Utility secondary outcome 9 Subgroup analysis of true positive rate (secondary utility outcome measure 2) by race, ethnicity, genetic ancestry, and disorder group. 5 years
Secondary Utility secondary outcome 10 Subgroup analysis of the proportion of BeginNGS and state NBS of DBS that are true positive and diagnosed during infancy in infancy by race, ethnicity, genetic ancestry, and disorder group. 5 years
Secondary Acceptability outcome 1 Proportion of parents approached who agree to enroll their newborn (Figure 1c?). This is a "key outcome" (as defined by CONSORT PRO31). 5 years
Secondary Acceptability outcome 2 Physician and parental questionnaires (Figure 1c?) regarding perceptions of benefits and harms of BeginNGS by parents and primary care pediatricians. 5 years
Secondary Acceptability outcome 3 Subgroup analysis of enrollment rate (proportion of parents approached who agree to enroll their newborn; Figure 1c?) by race, ethnicity, genetic ancestry, and enrollment method. 5 years
Secondary Acceptability outcome 4 Subgroup analysis of parental questionnaires (regarding perceptions of benefits and harms of BeginNGS) by race, ethnicity, and genetic ancestry. 5 years
Secondary Feasibility (ability of the study to be undertaken as designed) outcome 1 Time to return of a result for BeginNGS and state NBS. 5 years
Secondary Feasibility (ability of the study to be undertaken as designed) outcome 2 Time to return of a confirmed true positive result of BeginNGS and state NBS. 5 years
Secondary Feasibility (ability of the study to be undertaken as designed) outcome 3 Proportion of enrollees with positive results who undergo confirmatory testing by BeginNGS and state NBS. 5 years
Secondary Feasibility (ability of the study to be undertaken as designed) outcome 4 Time to diagnosis (time until a clinical feature of the disorder is identified) for BeginNGS and state NBS. 5 years
Secondary Feasibility (ability of the study to be undertaken as designed) outcome 5 Proportion of enrollees lost to follow up at one year of age. 5 years
Secondary Cost effectiveness outcome 1 Average cost effectiveness ratio (ACER, average cost to prevent one infant death or adverse event). 5 years
Secondary Cost effectiveness outcome 2 Incremental cost effectiveness ratio (ICER, average change in cost associated with prevention of one infant death or adverse event). 5 years
Secondary Cost effectiveness outcome 3 Subgroup analysis of Average Cost Effectiveness Ratio (ACER, average cost to prevent one infant death or adverse event) by disorder group (for example metabolic disorders, immunodeficiency disorders, seizure disorders, endocrine disorders, vitamin and cofactor deficiency disorders, hematologic disorders, muscle disorders). 5 years
Secondary Cost effectiveness outcome 4 Subgroup analysis of Incremental cost effectiveness ratio (ICER, average change in cost associated with prevention of one infant death or adverse event) by disorder group (for example metabolic disorders, immunodeficiency disorders, seizure disorders, endocrine disorders, vitamin and cofactor deficiency disorders, hematologic disorders, muscle disorders). 5 years
Secondary Accuracy outcome 1 True positive rate (true positive/true positive+false negative, recall, sensitivity) of BeginNGS by comparison with state NBS of DBS (all enrollees). 5 years
Secondary Accuracy outcome 2 True positive rate of BeginNGS by comparison with other genetic tests (in infants who subsequently receive diagnostic testing for a suspected genetic disease). 5 years
Secondary Utility secondary outcome 11 Number needed to screen to prevent one infant death or adverse event. 5 years
Secondary Feasibility outcome 6 Incidence of variants and haplotypes associated with individual genetic diseases in newborns. 5 years
Secondary Feasibility outcome 7 Categorical determination of genetic pattern of inheritance (for example dominant, recessive) of individual genetic diseases in newborns (where this has not been unequivocally established). 5 years
Secondary Utility secondary outcome 12 Subgroup categorical analysis of efficacy of individual therapeutic interventions in infants. 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Completed NCT03292302 - Phase 1 Study of ELX-02 in Healthy Adults Phase 1
Withdrawn NCT03658382 - Virtual Visits for Results Disclosure N/A
Recruiting NCT02266615 - Biobank Clinical Genetics Maastricht (KG01)
Recruiting NCT02450851 - Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
Recruiting NCT05472714 - Educational Video for Genetic Testing N/A
Recruiting NCT04285814 - Technology Development for Noninvasive Prenatal Genetic Diagnosis Using Whole Fetal Cells From Maternal Peripheral Blood
Completed NCT05443113 - Young Pectus Excavatum Patients and Genetic Defects
Completed NCT05655741 - Modified Delphi for Genomic Bereavement Care
Completed NCT03847909 - A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 Phase 2
Completed NCT04584528 - Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease N/A
Not yet recruiting NCT06048523 - Prospective Cohort Study of Neurogenetic Diseases N/A
Completed NCT02225522 - Genomic Sequencing in Acutely Ill Neonates N/A
Enrolling by invitation NCT06089954 - Penn Medicine Biobank Return of Results Program N/A
Completed NCT03713333 - Implementing Digital Health in a Learning Health System N/A
Completed NCT03309605 - Phase 1 Study of ELX-02 in Healthy Adult Subjects Phase 1
Recruiting NCT05499091 - Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN N/A
Completed NCT04556487 - Turkish Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)
Completed NCT04556500 - Turkish Version of the Affordance in the Home Environment for Motor Development-Toddler (AHEMD-T)
Recruiting NCT02551081 - Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units